The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Piclidenoson in Trials for Psoriasis & RA; Plus Duzallo Approved in Europe

Piclidenoson in Trials for Psoriasis & RA; Plus Duzallo Approved in Europe

September 18, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Piclidenoson in Trials for Psoriasis & RA
Piclidenoson (CF101), an oral A3 adenosine receptor agonist, is currently under development for treating autoimmune inflammatory diseases. The first patients are being enrolled in the phase 3 Comfort trial, which will evaluate the safety and efficacy of piclidenoson for treating moderate to severe plaque psoriasis.1

You Might Also Like
  • FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout
  • Sarilumab Approval Stalled; Piclidenoson Promising for Psoriasis
  • FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis
Also By This Author
  • Celltrion Accelerates U.S. Launch of Infliximab-dyyb, a Remicade Biosimilar

The Comfort trial will include 407 adult patients in Europe, Canada and Israel to evaluate and compare twice daily piclidenoson in 2 or 3 mg doses with 30 mg apremilast and/or placebo given twice daily. The study will run for 32 weeks, with the option to continue treatment through 48 weeks.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Additionally, piclidenoson is being evaluated in a phase 2 trial as a first line treatment for rheumatoid arthritis.

Duzallo Approved in Europe
The European Commission has approved the fixed-dose combination therapy of allopurinol and lesinurad (Duzallo) for treating gout.2 Allopurinol/lesinurad is indicated for treating hyperuricemia in adult gout patients who have been unable to reach target uric acid serum levels with allopurinol monotherapy.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Allopurinol decreases uric acid production, while lesinurad increases urinary excretion of uric acid, thus, leading to better control of uric acid levels. Lesinurad is the first novel uricosuric approved in Europe to treat gout in more than 40 years. Marketing authorization has been granted for the 28 European Union states and the European Economic Area countries including Norway, Iceland and Liechtenstein. This approval was based on the positive opinion adopted by the Committee for Medicinal Products for Human Use of the European Medicines Agency in June 2018.

The launch of this agent is planned for most European countries in 2019.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Can-Fite BioPharma. News release: Can-Fite announces enrollment of first patient in its Comfort phase III trial of piclidenoson in psoriasis. 2018 Aug 21.
  2. Harpaz Z, Silverman MM. CF101 Therapy in Patients with Moderate-to-severe plaque psoriasis (NCT03168256). ClinicalTrials.gov. 2018 April 4.
  3. Grünenthal. News release: Duzallo, a fixed-dose combination therapy for gout, approved in Europe. FirstWord Pharma. 2018 Aug 28.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Duzallo, Europe, International, piclidenoson, Psoriasis, Rheumatoid Arthritis (RA)

You Might Also Like:
  • FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout
  • Sarilumab Approval Stalled; Piclidenoson Promising for Psoriasis
  • FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis
  • FDA Approves Lesinurad + Allopurinol

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)